Browse by category

First patient dosed in trial of SYNT-101 for obesity

The first patient has been dosed in Syntis Bio's the Phase 1/1b SYNTIETY-1 clinical trial of SYNT-101, the company’s lead investigational program for the treatment of obesity. SYNT-101 is designed as a once-daily oral pill that redirects nutrient absorption past the small intestine’s duodenum, mimicking the effects of gastric bypass surgery. SYNT-101 works by transiently blocking nutrient absorption in the duodenum, the upper part of the small intestine, and redirecting nutri

First-in-human study of once-daily SYNT-101 oral treatment for obesity that mimics metabolic effects of gastric bypass without surgery

A first-in-human study of an investigational once-daily oral treatment for obesity (SYNT-101) demonstrated positive preliminary data for...

SYNT-101 once-daily oral treatment for obesity mimics RYGB

Syntis Bio has announced positive preclinical and first-in-human data for its lead candidate, SYNT-101, an investigational once-daily...

More than half of those who stop GLP-1s restart within a year

2 days ago

Coalition of Swiss organisations publish new Guidelines on Obesity

2 days ago

Study strengthens the case for insurers and policymakers to support coverage and improve access to MBS

2 days ago

Browse by category

First patient dosed in trial of SYNT-101 for obesity

First-in-human study of once-daily SYNT-101 oral treatment for obesity that mimics metabolic effects of gastric bypass without surgery

SYNT-101 once-daily oral treatment for obesity mimics RYGB

Browse by tag

More than half of those who stop GLP-1s restart within a year

Coalition of Swiss organisations publish new Guidelines on Obesity

Study strengthens the case for insurers and policymakers to support coverage and improve access to MBS

Back to Top